Part of university of georgia system board of regents
Clinical Trials
59
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1913
Active, not recruiting
3
5.1%
Completed
35
59.3%
Not yet recruiting
1
1.7%
Recruiting
13
22.0%
Suspended
1
1.7%
Terminated
1
1.7%
Unknown
1
1.7%
Withdrawn
4
6.8%
No approval data available
- GHP-88310, a broad-spectrum viral polymerase inhibitor, completely blocked airborne and direct-contact transmission of a measles-like virus in a ferret model. - Prophylactic administration before or after exposure prevented viral spread, while therapeutic use shortened the infectious period in already-infected animals. - The study, published in Nature Microbiology, modeled real-world transmission scenarios including household contact and classroom-style airborne exposure. - Researchers at Georgia State University are now preparing GHP-88310 for formal clinical testing amid resurgent measles outbreaks across North America.
- DZ-002, a novel fluorescent dye-drug conjugate developed by Georgia State University and Da Zen Theranostics, has advanced to Phase 2 clinical trials targeting pancreatic cancer patients. - The therapy utilizes MHI-148, a compound that selectively binds to cancer cells and delivers targeted radiation while minimizing damage to healthy tissues. - Phase 2 trials will evaluate safety, dosage parameters, and therapeutic efficacy in pancreatic cancer patients at HOAG Cancer Center, focusing on extending remission and improving quality of life. - The treatment represents 14 years of research and offers potential applications for other solid tumors and lymphoma beyond pancreatic cancer.
